Jonakayem Pharma Formulation (OPC) Pvt. Ltd.
CARBOPROST

CARBOPROST

Send Inquiry
Product: CARBOPROST
Formulary: Generic Formulary
Category: Genito Urinary System
Sub Group: DRUGS ACTING ON UTERUS
International Brand Name: Hemabate
Dosages: 125MG/ML
Unit of Packing: Inj-0.5ml
In treatment of: Termination of pregnency 2nd Trimester,treatment of postpartum haemorrhage

Contraiindication: 

  • Hypersensitivity to the drug. 
  • Cardiovascular diseases. 
  • Kidney disease. 
  • Liver disease. 
  • Lung disease. 
  • Recent infection of the ovaries, fallopian tubes and uterus

Special Precaution: 

  • Anemia. 
  • Asthma. 
  • Diabetes.
  • Epilepsy.
  • Glaucoma.
  • High blood pressure. 
  • Jaundice. 
  • Hypotension. 
  • Scarring of the womb.

Adverse Effects: 

  • Headache.
  • Dizziness.
  • Nausea.
  • Vomiting. 
  • Cardiac arrest. 
  • Wheezing. 
  • Redness around injection site. 
  • Diarrhoea. 
  • Facial flushing. 
  • Increase in body temperature. 
  • Hypertension. 
  • Pulmonary oedema

Interaction: Oxytocin: Activity of oxytocin augmented and hence should be used sequentially and carefully monitored. Hyperosmolar Urea: Prior injection of urea enhances activity of carboprost. Mifepristone: Enhanced activity with fewer side effects.

Servings: Intramuscular- Adults- Termination of pregnancy: 250 mcg at intervals of 1.5-3.5 hours, depending on uterine response; may increase dose to 500 mcg if contractility is inadequate after several 250 mcg doses. Dose should not exceed 2 mg Control of hemorrhage: 250 mcg; additional doses may be administered between 15 and 90 minutes apart if needed. Dose should not exceed 2 mg Catheterization- Hemorrhagic Cystitis: 400-500mcg diluted in 50mL NS and instilled into the bladder; clamp catheter and allow solution to dwell for 60 minutes; repeat every 6 hours until response. Patient should change positions every 15 minutes while carboprost is in bladder